SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS),
Thursday, too, saw Exscientia raise more than just the IPO. In conjunction with the pricing, the Oxford, UK-based biotech got another $160 million in private placements from SoftBank and the Bill and Melinda Gates Foundation. With the debut, details about the big IPO winners are coming into focus. The biggest shareholder is now SoftBank, which will get a 16.3% stake after the offering. CEO Andrew Hopkins is second on the list with 15.8% of shares.
Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing.Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.